Long-Term Therapy Outcomes When Treating Chronic Kidney Disease Patients with Paricalcitol in German and Austrian Clinical Practice (TOP Study)

Paricalcitol is approved for prevention and therapy of secondary hyperparathyroidism (sHPT) in patients with chronic kidney disease (CKD), with only short-term data in clinical routine settings. A 12-month observational study was conducted in Germany and Austria (90 centers, 761 patients) from 2008...

Descripción completa

Detalles Bibliográficos
Autores principales: Obermüller, Nicholas, Rosenkranz, Alexander R., Müller, Hans-Walter, Hidde, Dennis, Veres, András, Decker-Burgard, Sabine, Weisz, Isolde, Geiger, Helmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666739/
https://www.ncbi.nlm.nih.gov/pubmed/28956807
http://dx.doi.org/10.3390/ijms18102057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666739/
https://www.ncbi.nlm.nih.gov/pubmed/28956807
http://dx.doi.org/10.3390/ijms18102057

Ejemplares similares